• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Development of pseudotyped VSV-SARS-CoV-2 spike variants for the assessment of neutralizing antibodies.用于评估中和抗体的假型 VSV-SARS-CoV-2 刺突变异株的开发。
Bioanalysis. 2024;16(21-22):1167-1177. doi: 10.1080/17576180.2024.2411920. Epub 2024 Oct 16.
2
Establishment of human post-vaccination SARS-CoV-2 standard reference sera.建立人接种 SARS-CoV-2 疫苗后标准参考血清。
J Immunol Methods. 2024 Jul;530:113698. doi: 10.1016/j.jim.2024.113698. Epub 2024 May 31.
3
Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.利用具有 SARS-CoV-2 刺突蛋白的水疱性口炎病毒评估 SARS-CoV-2 中和抗体。
Virol J. 2021 Jan 12;18(1):16. doi: 10.1186/s12985-021-01490-7.
4
Anti-SARS-CoV-2 total immunoglobulin and neutralising antibody responses in healthy blood donors throughout the COVID-19 pandemic: a longitudinal observational study.在整个 COVID-19 大流行期间健康献血者的抗 SARS-CoV-2 总免疫球蛋白和中和抗体反应：一项纵向观察研究。
Swiss Med Wkly. 2024 Jul 1;154:3408. doi: 10.57187/s.3408.
5
An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.SARS-CoV-2 血清学检测作为真实病毒中和的替代指标的评估。
Microbiol Spectr. 2021 Oct 31;9(2):e0105921. doi: 10.1128/Spectrum.01059-21. Epub 2021 Oct 27.
6
Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells.基于携带 SARS-CoV-2 S 蛋白的水疱性口炎病毒（VSV）假病毒和过表达 ACE2 的 BHK21 细胞的稳健中和测定法。
Emerg Microbes Infect. 2020 Dec;9(1):2105-2113. doi: 10.1080/22221751.2020.1815589.
7
Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals.免疫抑制个体和健康个体接种单价奥密克戎JN.1适应性mRNA新冠疫苗后的中和抗体及T细胞针对刺突蛋白的反应
J Med Virol. 2025 Jun;97(6):e70463. doi: 10.1002/jmv.70463.
8
A pan-beta-coronavirus vaccine bearing conserved and asymptomatic B- and T-cell epitopes protects against highly pathogenic Delta and highly transmissible Omicron SARS-CoV-2 variants.一种携带保守且无症状的B细胞和T细胞表位的泛β冠状病毒疫苗可抵御高致病性德尔塔毒株和高传播性奥密克戎SARS-CoV-2变体。
Hum Vaccin Immunother. 2025 Dec;21(1):2527438. doi: 10.1080/21645515.2025.2527438. Epub 2025 Jul 4.
9
Antibody Levels From High-Throughput Variant-Specific SARS-CoV-2 Anti-Spike Immunoglobulin G and Angiotensin-Converting Enzyme 2 Neutralization Assays Correlate With COVID-19 Infection Risk in a Large Population.高通量变异株特异性SARS-CoV-2抗刺突免疫球蛋白G和血管紧张素转换酶2中和试验检测的抗体水平与大量人群的COVID-19感染风险相关。
J Infect Dis. 2025 Apr 15;231(4):921-930. doi: 10.1093/infdis/jiae622.
10
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.通过 SARS-CoV-2 刺突蛋白变体逃避中和抗体。
Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.

本文引用的文献

1
Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture.羟氯喹阻断 SARS-CoV-2 在哺乳动物细胞培养中的内吞途径进入。
Commun Biol. 2022 Sep 14;5(1):958. doi: 10.1038/s42003-022-03841-8.
2
Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.异源接种灭活疫苗后再接种 mRNA 加强针可诱导针对 SARS-CoV-2 奥密克戎变异株的强烈免疫应答。
Nat Commun. 2022 May 13;13(1):2670. doi: 10.1038/s41467-022-30340-5.
3
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.在接种两剂科兴疫苗的健康成年人中进行异源加强针后对奥密克戎变异株的中和活性。
J Infect Dis. 2022 Oct 17;226(8):1372-1381. doi: 10.1093/infdis/jiac092.
4
Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019.用于研究针对2019冠状病毒病的变体、疫苗和疗法的假型化水泡性口炎病毒-严重急性呼吸综合征冠状病毒2-刺突蛋白
Front Microbiol. 2022 Jan 14;12:817200. doi: 10.3389/fmicb.2021.817200. eCollection 2021.
5
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.在英国（Com-COV2）进行的包含 mRNA、病毒载体和蛋白佐剂疫苗的异源 COVID-19 初级疫苗接种的免疫原性、安全性和反应原性：一项单盲、随机、2 期、非劣效性试验。
Lancet. 2022 Jan 1;399(10319):36-49. doi: 10.1016/S0140-6736(21)02718-5. Epub 2021 Dec 6.
6
The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2.异源免疫初免-加强接种新冠疫苗对严重急性呼吸综合征冠状病毒2的影响
Vaccines (Basel). 2021 Oct 11;9(10):1163. doi: 10.3390/vaccines9101163.
7
Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates.大规模分析 SARS-CoV-2 刺突糖蛋白突变体表明需要持续筛选病毒分离物。
PLoS One. 2021 Sep 27;16(9):e0249254. doi: 10.1371/journal.pone.0249254. eCollection 2021.
8
Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.接受免疫抑制治疗的患者对 SARS-CoV-2 疫苗接种的体液和 T 细胞反应。
Ann Rheum Dis. 2021 Oct;80(10):1322-1329. doi: 10.1136/annrheumdis-2021-220626. Epub 2021 Aug 6.
9
Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.用异源疫苗加强免疫可有效提高灭活 SARS-CoV-2 疫苗的保护免疫应答。
Emerg Microbes Infect. 2021 Dec;10(1):1598-1608. doi: 10.1080/22221751.2021.1957401.
10
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.接种 ChAdOx1 nCoV-19/BNT162b2 异源和同源疫苗后针对 SARS-CoV-2 变体的免疫反应。
Nat Med. 2021 Sep;27(9):1525-1529. doi: 10.1038/s41591-021-01449-9. Epub 2021 Jul 14.

用于评估中和抗体的假型 VSV-SARS-CoV-2 刺突变异株的开发。

Development of pseudotyped VSV-SARS-CoV-2 spike variants for the assessment of neutralizing antibodies.

机构信息

Sabanci University Nanotechnology Research & Application Center (SUNUM), Istanbul, 34956, Turkey.

Faculty of Engineering & Natural Sciences, Molecular Biology, Genetics & Bioengineering Program, Sabanci University, Istanbul, 34956, Turkey.

出版信息

Bioanalysis. 2024;16(21-22):1167-1177. doi: 10.1080/17576180.2024.2411920. Epub 2024 Oct 16.

DOI:10.1080/17576180.2024.2411920
PMID:39411978
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11583609/
Abstract

Serological studies with pseudotyped viruses offer a safer alternative to live SARS-CoV-2 in evaluating neutralizing antibodies, enabling research in standard labs. The SARS-CoV-2 Spike pseudotyped vesicular stomatitis virus (VSV) pseudoviruses were generated using Spike of Wuhan strain and two variants (B.1.1.7, B.1.351) and utilized to evaluate the serum neutralizing activity of human plasma samples of vaccinated (n = 13) and healthy people (n = 2) compared with a plaque assay with authentic virus. Neutralizing titer of convalescent plasma resulted with a good correlation (R = 0.7). We evaluated a safe and reliable pseudotyped virus system that effectively mimics authentic virus and correlates well with traditional assays. The developed system allows easier testing of variants and has the potential to improve vaccine development.

摘要

用假型病毒进行血清学研究为评估中和抗体提供了一种比活 SARS-CoV-2 更安全的替代方法，使研究能够在标准实验室中进行。使用武汉株和两种变异株（B.1.1.7、B.1.351）的 SARS-CoV-2 刺突假型水疱性口炎病毒（VSV）假型病毒被生成，并用于评估接种疫苗者（n=13）和健康人（n=2）的人血浆样本的血清中和活性，与使用真实病毒的噬斑测定法进行比较。恢复期血浆的中和效价具有良好的相关性（R=0.7）。我们评估了一种安全可靠的假型病毒系统，该系统能有效模拟真实病毒，与传统检测方法相关性良好。该系统允许更轻松地检测变异株，并有潜力改进疫苗开发。